BBA
VERV

Baker Bros. Advisors’s Verve Therapeutics VERV Stock Holding History

Baker Bros. Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,691,530
Closed -$19M – 98
2025
Q2 		$19M Hold
1,691,530
– – 0.18% 39
2025
Q1 		$7.73M Hold
1,691,530
– – 0.09% 50
2024
Q4 		$9.54M Hold
1,691,530
– – 0.1% 54
2024
Q3 		$8.19M Hold
1,691,530
– – 0.08% 59
2024
Q2 		$8.25M Hold
1,691,530
– – 0.11% 54
2024
Q1 		$22.5M Hold
1,691,530
– – 0.28% 39
2023
Q4 		$23.6M Buy
1,691,530
+275,000
+19% +$3.41M 0.27% 36
2023
Q3 		$18.8M Hold
1,416,530
– – 0.11% 38
2023
Q2 		$26.6M Hold
1,416,530
– – 0.15% 37
2023
Q1 		$20.4M Hold
1,416,530
– – 0.11% 37
2022
Q4 		$27.4M Hold
1,416,530
– – 0.16% 32
2022
Q3 		$48.7M Hold
1,416,530
– – 0.32% 28
2022
Q2 		$21.6M Hold
1,416,530
– – 0.12% 47
2022
Q1 		$32.3M Hold
1,416,530
– – 0.19% 42
2021
Q4 		$52.2M Hold
1,416,530
– – 0.25% 35
2021
Q3 		$66.6M Hold
1,416,530
– – 0.29% 28
2021
Q2 		$85.3M Buy
+1,416,530
New +$58.8M 0.37% 24

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Baker Bros. Advisors's VERV Position: Q3 2025 in Review

Baker Bros. Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,691,530 shares — an estimated $19M sold.

Baker Bros. Advisors first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $85.3M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Baker Bros. Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,691,530 Verve Therapeutics shares in Q3 2025, an estimated $19M.
  • Baker Bros. Advisors first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Baker Bros. Advisors's Verve Therapeutics position peaked at $85.3M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Baker Bros. Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.